Advertisement
BIIB vs PFE
Which Stock Would AI Choose? Biogen Inc. (BIIB) vs. Pfizer Inc. (PFE) Stock Comparison
Key Takeaways
- Biogen (BIIB) delivered a strong one-year return of 54.68%, outperforming Pfizer (PFE)'s 18.02%, fueled by recent quarterly earnings beats.
- PFE offers a robust dividend yield of 6.53% and a much larger market capitalization of $149.8 billion compared to BIIB's $27.6 billion, appealing to income-focused investors.
- Both stocks trade at similar price-to-earnings (P/E) ratios around 20, but BIIB's lower beta of 0.19 indicates reduced volatility versus PFE's 0.31.
- Recent market activity shows BIIB benefiting from Q1 2026 revenue growth, while PFE anticipates pipeline catalysts amid patent expiration concerns.
- Tickeron AI currently favors PFE over BIIB with a 65% probability based on valuation and growth metrics.
Introduction
Biogen Inc. (BIIB) and Pfizer Inc. (PFE) represent contrasting profiles in the pharmaceutical sector: BIIB as a biotechnology specialist in neurology and PFE as a diversified global pharma giant. This stock comparison analyzes their recent performance, business models, and market positioning amid evolving healthcare demands and pipeline developments. Traders seeking momentum plays may eye BIIB's recent gains, while long-term investors might prefer PFE's stability and dividends. Understanding these dynamics aids in portfolio diversification and relative performance evaluation in the current market environment.
BIIB Overview and Recent Performance
Biogen Inc. (BIIB) focuses on biotechnology therapies, particularly for neurological disorders like multiple sclerosis (MS). Trading around $187 with a market cap of $27.6 billion, the stock has shown resilience, posting a year-to-date (YTD) gain of 6.29% and a one-year return of 54.68%. In recent market activity, BIIB reported Q1 2026 revenue of $2.5 billion, up 2% year-over-year and beating estimates, alongside earnings per share (EPS) of $3.57. However, sentiment has been tempered by a lowered full-year profit outlook due to mergers and acquisitions (M&A) costs and pressures on MS drugs. The stock's low beta of 0.19 reflects stability, with shares near the upper end of their 52-week range ($115-$202).
PFE Overview and Recent Performance
Pfizer Inc. (PFE), a leading pharmaceutical company with products in oncology, vaccines, and rare diseases, boasts a market cap of $149.8 billion. Shares trade near $26, with a YTD return of 7.51% and one-year gain of 18.02%. Recent weeks have seen modest declines amid broader market pressures, but positive analyst notes highlight upcoming pipeline catalysts and FDA approvals, with a $36 price target. Challenges include patent expirations and competition, influencing sentiment. PFE's forward dividend yield of 6.53% supports income strategies, and its beta of 0.31 indicates moderate volatility within its 52-week range ($22-$29). Earnings are slated for early May 2026.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the top-performing AI trading bots from a library of 351 bots that analyze and trade thousands of tickers across diverse strategies, timeframes, and sectors like semiconductors, data centers, and industrials. Only the most suitable for current conditions earn a spot among the 25 curated trending bots, with standout performances including annualized returns up to 163.10%, win rates ranging from 51% to 88.33%, and profit factors optimized via AI/ML models using take-profit/stop-loss corridors or trend-following. Examples feature multi-agent setups on ETFs and small caps yielding 50-100% returns. These bots offer varied styles from swing trading to volatility plays, enabling copy trading. Explore Trending AI Robots to identify tools matching your market outlook.
Head-to-Head Comparison
BIIB and PFE differ sharply in business models: BIIB's biotechnology emphasis on neurology exposes it to higher R&D risks but potential blockbuster drugs, while PFE's diversified portfolio across vaccines and oncology provides steadier revenue streams. Growth drivers include BIIB's pipeline momentum post-Q1 beats versus PFE's acquisitions and FDA nods amid patent cliffs. Recent momentum favors BIIB's superior one-year gains, but PFE edges in YTD returns and dividend appeal. Risk factors weigh heavier on BIIB due to M&A impacts and MS competition, contrasted with PFE's scale mitigating sector exposures. Market sentiment reflects BIIB's rally sustainability questions against PFE's undervaluation narrative, with similar P/E ratios highlighting trade-offs in stability versus upside potential.
Tickeron AI Verdict
Tickeron’s AI models currently favor PFE over BIIB with a 65% probability, citing superior valuation in pharmaceuticals major relative to biotechnology, trend stability, and larger-scale positioning with dividend support. While BIIB exhibits stronger short-term momentum from earnings catalysts, PFE's pipeline developments and lower relative risk profile suggest higher probability of outperformance in the near term.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a Buy and PFE is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIIB’s FA Score shows that 2 FA rating(s) are green whilePFE’s FA Score has 0 green FA rating(s).
- BIIB’s FA Score: 2 green, 3 red.
- PFE’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIIB’s TA Score shows that 4 TA indicator(s) are bullish while PFE’s TA Score has 4 bullish TA indicator(s).
- BIIB’s TA Score: 4 bullish, 4 bearish.
- PFE’s TA Score: 4 bullish, 5 bearish.
Price Growth
BIIB (@Pharmaceuticals: Major) experienced а +7.01% price change this week, while PFE (@Pharmaceuticals: Major) price change was +2.75% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +4.12%. For the same industry, the average monthly price growth was +16.27%, and the average quarterly price growth was +11.13%.
Reported Earning Dates
BIIB is expected to report earnings on Jul 29, 2026.
PFE is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+4.12% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| BIIB | PFE | BIIB / PFE | |
| Capitalization | 31.9B | 139B | 23% |
| EBITDA | 2.7B | 17.2B | 16% |
| Gain YTD | 22.802 | 0.946 | 2,410% |
| P/E Ratio | 21.47 | 19.15 | 112% |
| Revenue | 9.94B | 63.3B | 16% |
| Total Cash | 4.28B | 13.1B | 33% |
| Total Debt | 6.56B | 63.7B | 10% |
BIIB | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 20 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 87 Overvalued | 51 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 79 | 77 | |
PRICE GROWTH RATING 1..100 | 10 | 60 | |
P/E GROWTH RATING 1..100 | 13 | 41 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PFE's Valuation (51) in the Pharmaceuticals Major industry is somewhat better than the same rating for BIIB (87) in the Biotechnology industry. This means that PFE’s stock grew somewhat faster than BIIB’s over the last 12 months.
PFE's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as BIIB (100) in the Biotechnology industry. This means that PFE’s stock grew similarly to BIIB’s over the last 12 months.
PFE's SMR Rating (77) in the Pharmaceuticals Major industry is in the same range as BIIB (79) in the Biotechnology industry. This means that PFE’s stock grew similarly to BIIB’s over the last 12 months.
BIIB's Price Growth Rating (10) in the Biotechnology industry is somewhat better than the same rating for PFE (60) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew somewhat faster than PFE’s over the last 12 months.
BIIB's P/E Growth Rating (13) in the Biotechnology industry is in the same range as PFE (41) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew similarly to PFE’s over the last 12 months.
| BIIB | PFE | |
|---|---|---|
| RSI ODDS (%) | 5 days ago 77% | 5 days ago 57% |
| Stochastic ODDS (%) | 5 days ago 68% | 5 days ago 44% |
| Momentum ODDS (%) | 5 days ago 55% | 5 days ago 58% |
| MACD ODDS (%) | 5 days ago 58% | 5 days ago 64% |
| TrendWeek ODDS (%) | 5 days ago 58% | 5 days ago 55% |
| TrendMonth ODDS (%) | 5 days ago 60% | 5 days ago 55% |
| Advances ODDS (%) | 11 days ago 57% | 8 days ago 55% |
| Declines ODDS (%) | 21 days ago 71% | 6 days ago 58% |
| BollingerBands ODDS (%) | 5 days ago 68% | 5 days ago 56% |
| Aroon ODDS (%) | 5 days ago 58% | 5 days ago 59% |
Advertisement